RU2010102911A - Терапевтический агент для мезотелиомы - Google Patents
Терапевтический агент для мезотелиомы Download PDFInfo
- Publication number
- RU2010102911A RU2010102911A RU2010102911/15A RU2010102911A RU2010102911A RU 2010102911 A RU2010102911 A RU 2010102911A RU 2010102911/15 A RU2010102911/15 A RU 2010102911/15A RU 2010102911 A RU2010102911 A RU 2010102911A RU 2010102911 A RU2010102911 A RU 2010102911A
- Authority
- RU
- Russia
- Prior art keywords
- antibody
- mesothelioma
- therapeutic agent
- receptor
- human
- Prior art date
Links
- 206010027406 Mesothelioma Diseases 0.000 title claims abstract 28
- 239000003814 drug Substances 0.000 title claims abstract 27
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract 27
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims abstract 25
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims abstract 21
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims abstract 4
- 101001076414 Mus musculus Interleukin-6 Proteins 0.000 claims abstract 4
- 206010035603 Pleural mesothelioma Diseases 0.000 claims abstract 4
- 102000052611 human IL6 Human genes 0.000 claims abstract 4
- 102000005962 receptors Human genes 0.000 claims abstract 4
- 108020003175 receptors Proteins 0.000 claims abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 208000006178 malignant mesothelioma Diseases 0.000 claims abstract 2
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Mobile Radio Communication Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Терапевтический агент для мезотелиомы, который содержит антитело к рецептору интерлейкина-6 (IL-6) в качестве его активного ингредиента. ! 2. Терапевтический агент для мезотелиомы по п.1, где мезотелиома является плевральной мезотелиомой. ! 3. Терапевтический агент для мезотелиомы по п.2, где плевральная мезотелиома является злокачественной плевральной мезотелиомой. ! 4. Терапевтический агент для мезотелиомы по п.1, где антителом к IL-6-рецептору является моноклональное антитело к IL-6-рецептору. ! 5. Терапевтический агент для мезотелиомы по п.1, где антителом к IL-6-рецептору является моноклональное антитело к IL-6-рецептору человека. ! 6. Терапевтический агент для мезотелиомы по п.1, где антителом к IL-6-рецептору является моноклональное антитело к IL-6-рецептору мыши. ! 7. Терапевтический агент для мезотелиомы по любому из пп.1-5, где антителом к IL-6-рецептору является рекомбинантное антитело. ! 8. Терапевтический агент для мезотелиомы по п.5, где моноклональным антителом к IL-6-рецептору человека является антитело РМ-1. ! 9. Терапевтический агент для мезотелиомы по п.6, где моноклональным антителом к IL-6-рецептору мыши является антитело MR 16-1. ! 10. Терапевтический агент для мезотелиомы по любому из пп.4-6 и 8-9, где антителом к IL-6-рецептору является химерное антитело, гуманизированное антитело или человеческое антитело. ! 11. Терапевтический агент для мезотелиомы по п.7, где антителом к IL-6-рецептору является химерное антитело, гуманизированное антитело или человеческое антитело. ! 12. Терапевтический агент для мезотелиомы по п.10, где гуманизированным антителом к IL-6-рецептору является гуманизированное антитело РМ-1. ! 13. Терапевтический аген�
Claims (13)
1. Терапевтический агент для мезотелиомы, который содержит антитело к рецептору интерлейкина-6 (IL-6) в качестве его активного ингредиента.
2. Терапевтический агент для мезотелиомы по п.1, где мезотелиома является плевральной мезотелиомой.
3. Терапевтический агент для мезотелиомы по п.2, где плевральная мезотелиома является злокачественной плевральной мезотелиомой.
4. Терапевтический агент для мезотелиомы по п.1, где антителом к IL-6-рецептору является моноклональное антитело к IL-6-рецептору.
5. Терапевтический агент для мезотелиомы по п.1, где антителом к IL-6-рецептору является моноклональное антитело к IL-6-рецептору человека.
6. Терапевтический агент для мезотелиомы по п.1, где антителом к IL-6-рецептору является моноклональное антитело к IL-6-рецептору мыши.
7. Терапевтический агент для мезотелиомы по любому из пп.1-5, где антителом к IL-6-рецептору является рекомбинантное антитело.
8. Терапевтический агент для мезотелиомы по п.5, где моноклональным антителом к IL-6-рецептору человека является антитело РМ-1.
9. Терапевтический агент для мезотелиомы по п.6, где моноклональным антителом к IL-6-рецептору мыши является антитело MR 16-1.
10. Терапевтический агент для мезотелиомы по любому из пп.4-6 и 8-9, где антителом к IL-6-рецептору является химерное антитело, гуманизированное антитело или человеческое антитело.
11. Терапевтический агент для мезотелиомы по п.7, где антителом к IL-6-рецептору является химерное антитело, гуманизированное антитело или человеческое антитело.
12. Терапевтический агент для мезотелиомы по п.10, где гуманизированным антителом к IL-6-рецептору является гуманизированное антитело РМ-1.
13. Терапевтический агент для мезотелиомы по п.11, где гуманизированным антителом к IL-6-рецептору является гуманизированное антитело РМ-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-358152 | 2003-10-17 | ||
JP2003358152 | 2003-10-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006116896/15A Division RU2392967C2 (ru) | 2003-10-17 | 2004-10-15 | Терапевтический агент для мезотелиомы |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2010102911A true RU2010102911A (ru) | 2011-08-10 |
RU2554942C2 RU2554942C2 (ru) | 2015-07-10 |
Family
ID=34463281
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006116896/15A RU2392967C2 (ru) | 2003-10-17 | 2004-10-15 | Терапевтический агент для мезотелиомы |
RU2010102911/15A RU2554942C2 (ru) | 2003-10-17 | 2004-10-15 | Терапевтический агент для мезотелиомы |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006116896/15A RU2392967C2 (ru) | 2003-10-17 | 2004-10-15 | Терапевтический агент для мезотелиомы |
Country Status (23)
Country | Link |
---|---|
US (2) | US20070134242A1 (ru) |
EP (1) | EP1690550B1 (ru) |
JP (1) | JP4651541B2 (ru) |
KR (1) | KR101193708B1 (ru) |
CN (1) | CN1874790B (ru) |
AR (1) | AR046290A1 (ru) |
AU (1) | AU2004281139B2 (ru) |
BR (1) | BRPI0415505A (ru) |
CA (1) | CA2542691C (ru) |
DK (1) | DK1690550T3 (ru) |
ES (1) | ES2392824T3 (ru) |
HK (1) | HK1096588A1 (ru) |
IL (1) | IL174909A (ru) |
MX (1) | MXPA06003768A (ru) |
MY (1) | MY149856A (ru) |
NO (1) | NO20061906L (ru) |
NZ (1) | NZ546557A (ru) |
PL (1) | PL1690550T3 (ru) |
RU (2) | RU2392967C2 (ru) |
SI (1) | SI1690550T1 (ru) |
TW (1) | TWI350175B (ru) |
WO (1) | WO2005037315A1 (ru) |
ZA (1) | ZA200602973B (ru) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2312184T3 (es) | 1997-03-21 | 2009-02-16 | Chugai Seiyaku Kabushiki Kaisha | Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas. |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
EP2311489A3 (en) | 2002-02-14 | 2013-08-21 | Chugai Seiyaku Kabushiki Kaisha | Formulation of antibody-containing solutions comprising a sugar as a stabilizer |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
WO2005090405A1 (ja) | 2004-03-24 | 2005-09-29 | Chugai Seiyaku Kabushiki Kaisha | インターロイキン-6受容体に対するヒト型化抗体のサブタイプ |
AU2006300234B2 (en) | 2005-10-14 | 2013-01-10 | Chugai Seiyaku Kabushiki Kaisha | Agents for suppressing damage to transplanted islets after islet transplantation |
CN101330930B (zh) * | 2005-10-21 | 2011-11-23 | 中外制药株式会社 | 心脏病治疗剂 |
AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
US8771686B2 (en) * | 2006-01-27 | 2014-07-08 | Chugai Seiyaku Kabushiki Kaisha | Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody |
EP2006381B1 (en) | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
WO2007116962A1 (ja) | 2006-04-07 | 2007-10-18 | Osaka University | 筋再生促進剤 |
MX2009007830A (es) | 2007-01-23 | 2009-10-07 | Univ Shinshu | Inhibidor de rechazo cronico. |
US20090104187A1 (en) * | 2007-05-21 | 2009-04-23 | Alder Biopharmaceuticals, Inc. | Novel Rabbit Antibody Humanization Methods and Humanized Rabbit Antibodies |
US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
WO2008144763A2 (en) * | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to il-6 and use thereof |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
SG193868A1 (en) | 2007-09-26 | 2013-10-30 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
ES2563483T3 (es) | 2008-04-11 | 2016-03-15 | Chugai Seiyaku Kabushiki Kaisha | Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno |
TWI528973B (zh) * | 2008-06-05 | 2016-04-11 | Chugai Pharmaceutical Co Ltd | Nerve infiltration inhibitor |
JP5551593B2 (ja) * | 2008-07-30 | 2014-07-16 | 国立大学法人 岡山大学 | 新規悪性中皮腫治療剤及び免疫賦活化剤 |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
SG171804A1 (en) * | 2008-11-25 | 2011-07-28 | Alder Biopharmaceuticals Inc | Antibodies to il-6 and use thereof |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
JP5752038B2 (ja) * | 2009-07-31 | 2015-07-22 | 愼 前田 | 癌の転移抑制剤 |
JP5711751B2 (ja) | 2009-10-26 | 2015-05-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | グリコシル化された免疫グロブリンの調製方法 |
WO2011066369A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to raise albumin and/or lower crp |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
AR080428A1 (es) | 2010-01-20 | 2012-04-11 | Chugai Pharmaceutical Co Ltd | Formulaciones liquidas estabilizadas contentivas de anticuerpos |
US9539322B2 (en) * | 2010-05-28 | 2017-01-10 | National University Corporation Hokkaido University | Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody |
CN103180461A (zh) * | 2010-07-25 | 2013-06-26 | 纽约大学 | 用于间皮瘤预后的组合物和方法 |
MX2013005024A (es) | 2010-11-08 | 2013-11-21 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-il-6 receptor administrado subcutaneamente. |
ES2847891T3 (es) | 2010-11-23 | 2021-08-04 | Vitaeris Inc | Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral |
US20140234340A1 (en) | 2010-11-30 | 2014-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
EP2681243B1 (en) | 2011-03-03 | 2018-09-05 | Apexigen, Inc. | Anti-il-6 receptor antibodies and methods of use |
EP3011974B1 (en) | 2011-06-02 | 2018-08-08 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
MX339762B (es) | 2011-09-28 | 2016-05-27 | Univ Autonoma Del Estado De Morelos | Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen. |
JO3370B1 (ar) | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
CN105025923B (zh) | 2012-12-06 | 2018-03-27 | 国立大学法人金泽大学 | 间皮瘤的治疗方法 |
US10782290B2 (en) | 2013-06-11 | 2020-09-22 | National Center Of Neurology And Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy |
CA2913687C (en) | 2013-07-04 | 2022-12-13 | F. Hoffmann-La Roche Ag | Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples |
AU2016224409B2 (en) | 2015-02-27 | 2021-01-28 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
WO2016179394A1 (en) | 2015-05-05 | 2016-11-10 | Malik Mohammad Tariq | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
PL3299810T3 (pl) | 2015-05-19 | 2021-12-13 | National Center Of Neurology And Psychiatry | Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm) |
WO2017147169A1 (en) | 2016-02-22 | 2017-08-31 | Ohio State Innovation Foundation | Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites |
WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
WO2018170405A1 (en) | 2017-03-17 | 2018-09-20 | Ohio State Innovation Foundation | Nanoparticles for delivery of chemopreventive agents |
EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
JP2022527972A (ja) | 2019-04-02 | 2022-06-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前悪性病変を有する患者において癌を予測及び予防する方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US521628A (en) | 1894-06-19 | Housekeeping-cabinet | ||
US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
JP2914672B2 (ja) | 1989-01-17 | 1999-07-05 | 中外製薬株式会社 | Bsf▲下2▼アンタゴニスト |
SG42954A1 (en) * | 1989-07-20 | 1997-10-17 | Tadamitsu Kishimoto | Antibody to human interleukin-6 receptor |
JP2898040B2 (ja) | 1990-01-26 | 1999-05-31 | 忠三 岸本 | gp130蛋白質に対する抗体 |
US5210075A (en) | 1990-02-16 | 1993-05-11 | Tanabe Seiyaku Co., Ltd. | Interleukin 6 antagonist peptides |
AU668349B2 (en) | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
FR2694767B1 (fr) | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
AU7967294A (en) | 1993-10-06 | 1995-05-01 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
JPH07324097A (ja) | 1994-05-30 | 1995-12-12 | Daicel Chem Ind Ltd | インターロイキン6拮抗剤、及びペプチド類または医薬として許容されるその塩類 |
CN101011574B (zh) * | 1994-10-21 | 2012-10-03 | 岸本忠三 | Il-6受体的抗体在制备药物组合物中的用途 |
IT1274350B (it) | 1994-12-06 | 1997-07-17 | Angeletti P Ist Richerche Bio | Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130 |
IT1274782B (it) | 1994-12-14 | 1997-07-24 | Angeletti P Ist Richerche Bio | Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 |
JPH08245414A (ja) * | 1995-01-27 | 1996-09-24 | Private Biolog Corp | Il−6関連疾患の治療用組成物および方法 |
FR2733250B1 (fr) | 1995-04-21 | 1997-07-04 | Diaclone | Anticorps monoclonaux anti-gp130, et leurs utilisations |
JPH08311098A (ja) | 1995-05-22 | 1996-11-26 | Daicel Chem Ind Ltd | 新規ペプチド類およびそれを含有するインターロイキン6拮抗剤 |
US5571513A (en) | 1995-05-31 | 1996-11-05 | The Board Of Regents Of The University Of Oklahoma | Anti-gp130 monoclonal antibodies |
AU6038196A (en) * | 1995-06-07 | 1996-12-30 | Private Biologicals Corporation | Compositions and methods of treating il-6 associated disease s |
US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
PL201461B1 (pl) * | 1998-03-17 | 2009-04-30 | Chugai Pharmaceutical Co Ltd | Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny |
AU2066301A (en) * | 1999-12-09 | 2001-06-18 | Human Genome Sciences, Inc. | Il-6 like polynucleotide |
DK1334731T3 (da) | 2000-10-25 | 2008-05-26 | Chugai Pharmaceutical Co Ltd | Forebyggende eller terapeutisk middel mod psoriasis omfattende anti-IL-6-receptorantistof som aktiv bestanddel |
AU2000279625A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
AU2004204261A1 (en) * | 2003-01-15 | 2004-07-29 | Solbec Pharmaceuticals Limited | Method of modulating IL-6 |
US20050090453A1 (en) * | 2003-01-15 | 2005-04-28 | Solbec Pharmaceuticals Co., Ltd. | Methods of modulating IL-6 |
EP1594897A4 (en) * | 2003-02-04 | 2006-11-08 | Centocor Inc | USE OF IL-6 ANTAGONISTS IN COMBINATION WITH STEROIDS FOR INCREASED APOPTOSIS |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
US20060094645A1 (en) * | 2004-10-06 | 2006-05-04 | Oliver Lawless | Method for defining and treating chemically-induced immune disorders using tumor necrosis factor (TFNalpha), interleukin-1 (lL-1), and interleulin-6R(lL-6R) antagonists |
-
2004
- 2004-10-15 RU RU2006116896/15A patent/RU2392967C2/ru not_active IP Right Cessation
- 2004-10-15 AR ARP040103743A patent/AR046290A1/es unknown
- 2004-10-15 CA CA2542691A patent/CA2542691C/en not_active Expired - Fee Related
- 2004-10-15 MX MXPA06003768A patent/MXPA06003768A/es active IP Right Grant
- 2004-10-15 NZ NZ546557A patent/NZ546557A/en not_active IP Right Cessation
- 2004-10-15 TW TW093131346A patent/TWI350175B/zh not_active IP Right Cessation
- 2004-10-15 US US10/575,455 patent/US20070134242A1/en not_active Abandoned
- 2004-10-15 MY MYPI20044273A patent/MY149856A/en unknown
- 2004-10-15 EP EP04792816A patent/EP1690550B1/en active Active
- 2004-10-15 BR BRPI0415505-0A patent/BRPI0415505A/pt not_active IP Right Cessation
- 2004-10-15 KR KR1020067007246A patent/KR101193708B1/ko not_active IP Right Cessation
- 2004-10-15 CN CN200480031888XA patent/CN1874790B/zh not_active Expired - Fee Related
- 2004-10-15 DK DK04792816.3T patent/DK1690550T3/da active
- 2004-10-15 AU AU2004281139A patent/AU2004281139B2/en not_active Ceased
- 2004-10-15 JP JP2005514876A patent/JP4651541B2/ja active Active
- 2004-10-15 WO PCT/JP2004/015674 patent/WO2005037315A1/ja active Application Filing
- 2004-10-15 SI SI200431946T patent/SI1690550T1/sl unknown
- 2004-10-15 RU RU2010102911/15A patent/RU2554942C2/ru not_active IP Right Cessation
- 2004-10-15 ES ES04792816T patent/ES2392824T3/es active Active
- 2004-10-15 PL PL04792816T patent/PL1690550T3/pl unknown
-
2006
- 2006-04-10 IL IL174909A patent/IL174909A/en not_active IP Right Cessation
- 2006-04-12 ZA ZA200602973A patent/ZA200602973B/en unknown
- 2006-04-28 NO NO20061906A patent/NO20061906L/no not_active Application Discontinuation
-
2007
- 2007-02-09 HK HK07101545.1A patent/HK1096588A1/xx not_active IP Right Cessation
-
2008
- 2008-04-10 US US12/081,126 patent/US8802092B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010102911A (ru) | Терапевтический агент для мезотелиомы | |
RU2010117171A (ru) | Терапевтические средства, используемые против реакции трансплантант против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6 | |
HUP0303952A2 (hu) | Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre | |
RU2006126092A (ru) | Профилактическое средство против васкулита | |
RU97108070A (ru) | Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образование il-6 | |
EA200870130A1 (ru) | Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6 | |
EA201300022A1 (ru) | Терапевтическое человеческое моноклональное антитело против il-1r1 | |
NZ568769A (en) | Human monoclonal antibodies against CD20 | |
ATE180511T1 (de) | Humanisierter b-b10, ein anti-il-2-rezeptor- antikörper | |
ATE513563T1 (de) | Therapeutische und toleranz-induzierende antikörper | |
DK0616537T3 (da) | CDw52-specifikt antistof til behandling af dissemineret sclerose | |
NO20054959D0 (no) | Fremgangsmater for behandling av interleukin-6 relaterte sykdommer | |
DK1572748T3 (da) | Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2 | |
EA200301213A1 (ru) | Лиганды рецепторов 5-ht и их применение | |
ES2291311T3 (es) | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidores de proteina quinasas. | |
BR0315123A (pt) | Composições farmacêuticas direcionadas a receptores erb-b1 | |
HUP0402653A2 (hu) | Interleukin 15-re (IL-15-re) specifikus emberi antitestek | |
MA29595B1 (fr) | Anticorps anti-cd40 humanises et procedes d'utilisation | |
NO20023957D0 (no) | Humaniserte antistoffer som binder A<beta>-peptid | |
DE60327205D1 (de) | Therapeutische antiköper mit reduzierten nebenwirkungen | |
EP0791359A4 (en) | MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES | |
ATE495248T1 (de) | Monoklonaler anti-cd20-antikörper | |
DK0578774T3 (da) | Monoklonale antistoffer mod stamcellefaktor-receptorer | |
EE200100667A (et) | CD20 vastaste antikehade kasutamine transplantaadi peremehevastase reaktsiooni raviks | |
BRPI0412245A (pt) | anticorpos de rg1 e usos destes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181016 |